Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.

Ramosetron
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth (ODT), IV
ATC code
  • None
Pharmacokinetic data
Elimination half-life5.8 hours
Identifiers
  • (1-Methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H17N3O
Molar mass279.343 g·mol−1
3D model (JSmol)
  • CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
  • InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1 ☒N
  • Key:NTHPAPBPFQJABD-LLVKDONJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5]

References

edit
  1. ^ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
  2. ^ "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
  3. ^ Summary in Japanese. Retrieved on September 4, 2012.
  4. ^ "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
  5. ^ Abridged prescribing information — Nasea (MIMS Philippines)[permanent dead link]. Retrieved on June 13, 2008.